An interventional study of Revision of Medical Records in Lung Cancer, Artificial Intelligence (AI) and Large Language Model, sponsored by Sir Run Run Shaw Hospital. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sir Run Run Shaw Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 845 studies in Lung Neoplasms with a site in China — 372 open to participants now, 419 under way, 34 of them phase 3. Lung Neoplasms · China.
Among the 845 studies in Lung Neoplasms with a site in China, this one is the 197th largest by planned enrollment of the 586 interventional ones that give a count, is one of 90 that started in 2026, is one of 213 with no phase, reaches primary completion later than 183 of the 418 other live ones, and was the 845th registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →372 of the 845 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–80
Xiamen University · Sites in China
Ages 18–80
AstraZeneca · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
845 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 137 · Phase 2 225 · Phase 3 77 · Phase 4 9
First in 1992; this study’s year is marked. 90 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Median enrollment 90 across the 586 interventional studies, 304 across the 258 observational. Of the 207 that completed or were terminated, 36 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
185 of 845 have an industry lead sponsor. The 10 most frequent:
Sir Run Run Shaw Hospital is the lead sponsor of 136 studies on the registry; 73 are open to participants now.
Sir Run Run Shaw Hospital has 4 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
117 of the studies in Lung Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607796Phase 3Zhou ChengzhiEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04841811Phase 3Guangdong Association of Clinical TrialsMDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | 2026-12-31 |
| NCT06598527Phase 3Yang HongStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study | 2027-01-30 |
Add all 117 to your calendar (.ics) → With an account.
Among the 845 studies in Lung Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn whether an artificial intelligence (AI) tool helps healthcare providers write and revise medical notes and check medical orders. This prospective study compares routine documentation without AI to documentation with AI assistance. The AI tool helps draft notes and review orders, but it does not make treatment decisions. Researchers will compare the quality of the notes, the time spent writing them, and the number of order errors between the two methods. The results will help hospitals decide if AI can improve daily clinical workflows.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Providers:
Patients:
Exclusion Criteria:
Providers:
Patients:
This study uses a before-and-after self-controlled design; therefore, it is a single-arm study.
Other: Revision of Medical Records
The intervention is an Artificial Intelligence (AI)-assisted clinical documentation tool integrated into the daily workflow of healthcare providers. The AI system assists providers by generating and revising clinical notes and double-checking medical orders. The tool functions solely as a documentation and verification aid; it does not make or alter clinical treatment decisions. This intervention is evaluated against standard, routine documentation practices to assess its impact on workflow efficiency, note quality, and order accuracy.
Document quality score
The PDQI-9 (The 9-Item Physician Documentation Quality Instrument) is used as the baseline scale. Each item on the baseline scale is scored on a scale of 1 to 5, with 1 being the worst and 5 being the best.
Time frame: Within one week after completing all medical records
Not enrolling at this site.
Plan to share: No — Individual participant data will not be shared due to ethical restrictions and to protect patient privacy and confidentiality.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
Of 868 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 3 months is below that.
Counting every sponsor, half of 919 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.